İkincil Aktif Ulaşım

Secondary active transport uses energy stored in ion electrochemical gradients rather than ATP directly. Primary active transport, like the sodium-potassium pump, establishes these gradients by consuming ATP. Secondary active transport then harnesses the resulting sodium gradient to move solutes like glucose against their concentration gradients without direct ATP use.

Sodium ions are maintained at higher concentrations outside cells, creating both a chemical and electrical gradient pointing inward. This electrochemical gradient provides the energy for secondary active transport. When sodium moves down its gradient through transport proteins, the released energy enables these proteins to move other solutes like glucose against their concentration gradients.

SGLT1 binds both sodium and glucose on the extracellular side. As sodium moves down its electrochemical gradient, the protein changes shape and gains affinity for glucose. Once both molecules bind, the transporter opens on the cytoplasm side, sodium detaches first, then glucose is released into the cell against its concentration gradient.

SGLT1 couples glucose transport to sodium movement down its electrochemical gradient. The energy released from sodium flowing inward powers a conformational change that increases the protein's affinity for glucose. This allows glucose to be transported uphill even when intracellular glucose levels exceed extracellular levels.

SGLTs are primarily located in the membranes of intestinal and kidney cells. These locations are critical for glucose absorption from the lumen of these organs into the bloodstream. This positioning allows efficient glucose uptake from dietary sources and urine filtration.

In diabetes, excess glucose in the bloodstream causes complications like nerve damage. Researchers are investigating whether inhibiting SGLT expression can reduce blood glucose levels. Similarly, cancer cells require more glucose than normal cells, so blocking glucose transporters may starve tumors and serve as a potential anti-cancer therapy.

After glucose is released, SGLT1's affinity for glucose decreases. The empty transporter returns to its original outward-facing position, exposing sodium-binding sites on the extracellular side. This resets the protein for another transport cycle, allowing continuous glucose uptake as long as the sodium gradient is maintained.